Cancer immunotherapy drug discovery outsourcing refers to the outsourcing of research activities that assist in optimizing the time and funds involved in the process of drug discovery. It is done for various types of cancer like breast cancer, lung cancer, melanoma, colorectal cancer, prostate cancer, ovarian & pancreatic cancer, and head & neck cancer.
Report Scope:
Report Attribute | Details |
---|---|
Base Year | 2020 |
Historic Years | 2016 - 2020 |
Forecast Years | 2021 - 2028 |
Segments Covered | By Product Type, By Application, and By End Use |
Forecast Units | Value (USD Billion), and Volume (Units) |
Quantitative Units | Revenue in USD million/billion and CAGR from 2021 to 2028 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
Number of Companies Covered | 10 companies with scope for including additional 15 companies upon request |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization Scope | Avail customized purchase options to meet your exact research needs. |
One of the major factors driving the global cancer immunotherapy drug discovery outsourcing market is the growing awareness regarding the advancements in cancer treatment therapies along with the growing investments by prominent pharmaceutical companies to outsource the various activities involved in the process of drug discovery for cancer treatments. Pharmaceutical companies are shifting their focus to immunotherapies as they are vital alternatives for the treatment of cancer due to their high ability to lower the potential risk of tumor recurrence post-chemotherapy. The outsourcing process of research activities reduces the time involved in the process and does help in optimizing the funds for better outcome of investment. The growing research and development activities to innovate novel drugs for the effective treatments of cancer are further fuelling the growth of the global cancer immunotherapy drug discovery outsourcing market. Moreover, the introduction of advanced therapeutic options like HDAC inhibitors, oncolytic viral therapies, cancer vaccines, and monoclonal antibodies is likely to positively shape the trajectory of the global cancer immunotherapy drug discovery outsourcing market.
The global cancer immunotherapy drug discovery outsourcing market can be segmented into cancer type, service, drug, and region.
By cancer type, the market can be segmented into pancreatic, ovarian, head & neck, prostate, melanoma, colorectal, breast, and lung. Lung cancer accounts for the largest share in the global market. The delayed diagnosis of lung cancer makes chemotherapy inefficient and this underlying drawback can be overcome with the help of immunotherapy. Immunotherapy is proven to be very effective in the treatment of non-small cell lung cancer. Moreover, the wide availability of immunotherapy is further propelling the growth of the segment. The ovarian segment is anticipated to grow vigorously during the forecast period due to the increasing research and development activities along with the rising prevalence of ovarian cancer all across the globe.
By service, the market can be segmented into cell-based assays, lead screening & characterization, and target identification & validation. The target identification & validation segment holds the largest share in the global cancer immunotherapy drug discovery outsourcing market. The growth can be attributed to the launch of novel drugs constantly in the market for the treatment of cancer patients.
By drug, the market can be segmented into oncolytic viral therapies and cancer vaccines immunomodulators, monoclonal antibodies, and others. The monoclonal antibodies segment holds hegemony over others in the global market.
North America accounts for the largest share in the global cancer immunotherapy drug discovery outsourcing market due to the presence of prominent market players, biotech, and big pharmaceutical companies in the region. Moreover, the growing demand for novel drugs to treat cancer therapy cancer patients along with the growing outsourcing trend in the region will also boost market growth.
Asia Pacific accounts for the second-largest share in the global market due to the introduction of advanced immunotherapy drugs in growing economies like Japan and China to treat cancer patients.
Some of the significant players in the global cancer immunotherapy drug discovery outsourcing market are Molecular Imaging, Inc., STC Biologics, Personalis, Inc., ImmunXperts SA, Celentyx Ltd., DiscoverX Corporation, Genscript Biotech Corporation, BPS Bioscience, Inc, Biosciences Co., Ltd., DiscoverX Corporation, Genscript Biotech Corporation, BPS Bioscience, Inc., HD Biosciences Co., Ltd., Promega Corporation, Crown Bioscience, Inc., Horizon Discovery Group PLC, Aquila BioMedical, Explicyte, and Covance, Inc.
FrequentlyAsked Questions
One of the major factors driving the global cancer immunotherapy drug discovery outsourcing market is the growing awareness regarding the advancements in cancer treatment therapies along with the growing investments by prominent pharmaceutical companies to outsource the various activities involved in the process of drug discovery for cancer treatments. Pharmaceutical companies are shifting their focus to immunotherapies as they are vital alternatives for the treatment of cancer due to their high ability to lower the potential risk of tumor recurrence, post-chemotherapy.
Some of the significant players in the global cancer immunotherapy drug discovery outsourcing market are Molecular Imaging, Inc., STC Biologics, Personalis, Inc., ImmunXperts SA, Celentyx Ltd., DiscoverX Corporation, Genscript Biotech Corporation, BPS Bioscience, Inc, and Biosciences Co., Ltd.
North America accounts for the largest share in the global cancer immunotherapy drug discovery outsourcing market due to the presence of prominent market players, biotech, and big pharmaceutical companies in the region.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed